Dr. Eggert is a board-certified, fellowship-trained pulmonologist and a clinical assistant professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at Stanford University School of Medicine.

She is an expert in the diagnosis and management of diseases of the airway, with a focus on patients with allergic asthma. She also treats chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and chronic cough.

For every patient, Dr. Eggert develops a comprehensive care plan personalized to the individual’s unique needs and lifestyle. Her goals are always to deliver innovative, compassionate care of the highest quality to help each patient achieve the best possible outcome and quality of life.

Dr. Eggert has extensive research experience. During her fellowship, she worked closely with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University, where she designed projects to study the use of biologic medications to treat severe asthma, ABPA, and related conditions.

Dr. Eggert has authored review articles on asthma in adults for BMJ Best Practice. She has developed abstracts related to the prediction of asthma outcomes and switching and combining biologic therapies for asthma. She has presented her work at the American Thoracic Society and the American Academy of Allergy and Immunology annual meetings.

She is currently involved in several COVID-19 related research projects, including a study of the impact of COVID-19 on outcomes for asthmatic patients and another on the use of pulse oximeters to predict clinical decline after COVID-19 diagnosis.

Dr. Eggert also practices critical care at Stanford Health Care - ValleyCare and is actively engaged in teaching residents and fellows. She precepts both the Stanford Pulmonary Consult Service and the fellow’s clinics.

Clinical Focus

  • Pulmonary Disease

Academic Appointments

Administrative Appointments

  • Medical Director, Stanford Health Care- ValleyCare Pulmonary Rehabilitation (2021 - Present)

Honors & Awards

  • Alpha Omega Alpha, AOA Honor Society (6/2013)

Boards, Advisory Committees, Professional Organizations

  • Program Committee Member, ATS (2021 - Present)

Professional Education

  • Board Certification: American Board of Internal Medicine, Critical Care Medicine (2020)
  • Fellowship: Stanford University Pulmonary and Critical Care Fellowship (2020) CA
  • Board Certification: American Board of Internal Medicine, Pulmonary Disease (2019)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2016)
  • Residency: Icahn School of Medicine at Mount Sinai Hospital Internal Medicine Residency (2016) NY
  • Medical Education: Albert Einstein College of Medicine Montefiore Medical Center (2013) NY

All Publications

  • Severity of COVID-19 in Patients on Biologics for Allergic Disease: A Retrospective Study of Two Tertiary Healthcare Systems Pathak, C., Jiang, S., Cao, S., Collins, W., Eggert, L., Chinthrajah, R. S., Akuthota, P. AMER THORACIC SOC. 2022
  • Precision Sleep Medicine: Variations in Sleep Quality Among Asian Americans in the National Health Interview Survey (2006-2018) Wang, R., Wang, Z., Jamal, A., Dan, S., Srinivasan, M., Eggert, L. AMER THORACIC SOC. 2022
  • COVID-19 and Biologics in Severe Asthmatic Patients: A Multicenter Retrospective Analysis Jiang, S. Y., Pathak, C., Cao, S., Collins, W., Eggert, L., Akuthota, P., Chinthrajah, R. S. AMER THORACIC SOC. 2022
  • Use of home pulse oximetry with daily short message service messages for monitoring outpatients with COVID-19: The patient's experience DIGITAL HEALTH Vaughan, L., Eggert, L. E., Jonas, A., Sung, A., Singer, S. 2021; 7: 20552076211067651


    Studies have shown COVID-19 patients may have a low oxygen saturation (SpO2) independent of visible respiratory distress, a phenomenon termed "silent hypoxia." Silent hypoxia creates uncertainty in the outpatient setting for clinicians and patients alike. In this study, we examined the potential for pulse oximeters in identifying early signs of clinical deterioration. We report descriptive results on COVID-positive patients' experiences with a comprehensive home monitoring tool comprised of home SpO2 measurements with a novel symptom-tracking short message service/text messaging application. Of patients who required hospitalization, 83% sought care as a result of low pulse oximeter readings. Nearly all patients who did not require hospitalization reported that having a pulse oximeter provided them with the confidence to stay at home. Essentially all patients found a home pulse oximeter useful. Keeping COVID-19-positive patients at home reduces the potential for disease spread and prevents unnecessary costs and strain on the healthcare system.

    View details for DOI 10.1177/20552076211067651

    View details for Web of Science ID 000731017000001

    View details for PubMedID 34925873

    View details for PubMedCentralID PMC8679026

  • Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy Eggert, L. E., He, Z., Collins, W., Lee, A. S., Dhondalay, G., Jiang, S. Y., Fitzpatrick, J., Snow, T. T., Pinsky, B. A., Artandi, M., Barman, L., Puri, R., Wittman, R., Ahuja, N., Blomkalns, A., O'Hara, R., Cao, S., Desai, M., Sindher, S. B., Nadeau, K., Chinthrajah, R. S. 2021


    BACKGROUND: It is unclear if asthma and its allergic phenotype are risk factors for hospitalization or severe disease from SARS-CoV-2.METHODS: All patients over 28 days oldtesting positive for SARS-CoV-2 between March 1 and September 30, 2020, were retrospectively identified and characterized through electronic analysis at Stanford. A sub-cohort was followed prospectively to evaluate long-term COVID-19 symptoms.RESULTS: 168,190 patients underwent SARS-CoV-2 testing, and 6,976 (4.15%) tested positive. In a multivariate analysis, asthma was not an independent risk factor for hospitalization (OR 1.12 [95% CI 0.86, 1.45], p=0.40). Among SARS-CoV-2 positive asthmatics, allergic asthma lowered the risk of hospitalization and had a protective effect compared to non-allergic asthma (OR 0.52 (0.28, 0.91), p=0.026); there was no association between baseline medication use as characterized by GINA and hospitalization risk. Patients with severe COVID-19 disease had lower eosinophil levels during hospitalization compared to patients with mild or asymptomatic disease, independent of asthma status (p=0.0014). In a patient sub-cohort followed longitudinally, asthmatics and non-asthmatics had similar time to resolution of COVID-19 symptoms, particularly lower respiratory symptoms.CONCLUSIONS: Asthma is not a risk factor for more severe COVID-19 disease. Allergic asthmatics were half as likely to be hospitalized with COVID-19 compared to non-allergic asthmatics. Lower levels of eosinophil counts (allergic biomarkers) were associated with a more severe COVID-19 disease trajectory. Recovery was similar among asthmatics and non-asthmatics with over 50% of patients reporting ongoing lower respiratory symptoms three months post-infection.

    View details for DOI 10.1111/all.14972

    View details for PubMedID 34080210

  • Asthma as a predictor of more severe outcomes in COVID-19 infection Eggert, L., Cao, S., He, Z., Dhondalay, G., Jiang, S., Collins, W., Sindher, S., Nadeau, K., Sharon Chinthrajah, R. MOSBY-ELSEVIER. 2021: AB44
  • Asthma as a predictor of more severe outcomes in COVID-19 infection Journal of Allergy and Clinical Immunology Eggert, L. E., Cao, S., He, Z., Sindher, S., Nadeau, K., Chinthrajah, R. 2021; 147 (2)
  • Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19 European Journal of Allergy and Clinical Immunology Eggert, L. E., He, Z., Collins, W., Lee, A. S., Nadeau, K., Chinthrajah, R. 2021

    View details for DOI 10.1111/all.14972

  • Asthma in Adults BMJ Best Practice Eggert, L., Majumdar, S. 2020
  • Acute Asthma Exacerbation in Adults BMJ Best Practice Majumdar, S., Eggert, L. 2020
  • Oncotype recurrence score (RS) and discordance in patients with secondary invasive breast events (SIBE). Zimmerman, B., Cascetta, K., Blanter, J., Eggert, L., Molot, M., Ru, M., Nayak, A., Bleiweiss, I., Jaffer, S., Tiersten, A. AMER SOC CLINICAL ONCOLOGY. 2019
  • Switching and Combining Biologics in Severe Asthma: Experience from a Large Academic Teaching Center Eggert, L., Chinthrajah, R. S. AMER THORACIC SOC. 2019
  • Retrospective analysis of oncotype DX recurrence score (RS) and discordance in patients with node-negative, ER+ breast cancer with recurrence Zimmerman, B. S., Cascetta, K. P., Ru, M., Eggert, L., Molot, M., Nayak, A., Bleiweiss, I., Tiersten, A. 2018

    View details for DOI 10.1158/1538-7445

  • One-Year Experience After Implementation of a Multidisciplinary Pulmonary Embolism Team ATS Eggert, L., Klipper, K., Kadian-Dodov, D., Reddy, R., DePalo, L., Lookstein, R., Poor, H. 2016